HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
“The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine,” added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.
Read more below.
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
This October, HTL Biotechnology turned pink to support breast cancer prevention.
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.